[go: up one dir, main page]

FR21C1000I1 - Combiaisons pharmaceutiques d'un antagoniste du recepteur de l'angiotensine et un inhibiteur de nep - Google Patents

Combiaisons pharmaceutiques d'un antagoniste du recepteur de l'angiotensine et un inhibiteur de nep

Info

Publication number
FR21C1000I1
FR21C1000I1 FR21C1000C FR21C1000C FR21C1000I1 FR 21C1000 I1 FR21C1000 I1 FR 21C1000I1 FR 21C1000 C FR21C1000 C FR 21C1000C FR 21C1000 C FR21C1000 C FR 21C1000C FR 21C1000 I1 FR21C1000 I1 FR 21C1000I1
Authority
FR
France
Prior art keywords
combiions
pharmaceutical
receptor antagonist
angiotensin receptor
nep inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1000C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma AG
Original Assignee
Novartis Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1000(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma AG filed Critical Novartis Pharma AG
Publication of FR21C1000I1 publication Critical patent/FR21C1000I1/fr
Application granted granted Critical
Publication of FR21C1000I2 publication Critical patent/FR21C1000I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR21C1000C 2005-11-09 2021-01-11 Combiaisons pharmaceutiques d'un antagoniste du recepteur de l'angiotensine et un inhibiteur de nep Active FR21C1000I2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US73509305P 2005-11-09 2005-11-09
US73554105P 2005-11-10 2005-11-10
US78933206P 2006-04-04 2006-04-04
US82208606P 2006-08-11 2006-08-11
EP06827689.8A EP1948158B1 (fr) 2005-11-09 2006-11-08 Combinaison pharmaceutiques d'un antagoniste de recepteur d'angiotensine et d'un inhibiteur de nep
PCT/US2006/043710 WO2007056546A1 (fr) 2005-11-09 2006-11-08 Combinaison pharmaceutiques d'un antagoniste de recepteur d'angiotensine et d'un inhibiteur de nep

Publications (2)

Publication Number Publication Date
FR21C1000I1 true FR21C1000I1 (fr) 2021-03-05
FR21C1000I2 FR21C1000I2 (fr) 2024-05-24

Family

ID=37908343

Family Applications (2)

Application Number Title Priority Date Filing Date
FR16C0018C Active FR16C0018I2 (fr) 2005-11-09 2016-05-17 Combinaison pharmaceutiques d'un antagoniste de recepteur d'angiotensine et d'un inhibiteur de nep
FR21C1000C Active FR21C1000I2 (fr) 2005-11-09 2021-01-11 Combiaisons pharmaceutiques d'un antagoniste du recepteur de l'angiotensine et un inhibiteur de nep

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR16C0018C Active FR16C0018I2 (fr) 2005-11-09 2016-05-17 Combinaison pharmaceutiques d'un antagoniste de recepteur d'angiotensine et d'un inhibiteur de nep

Country Status (36)

Country Link
US (12) US8877938B2 (fr)
EP (3) EP1948158B1 (fr)
JP (3) JP4824754B2 (fr)
KR (2) KR101549318B1 (fr)
CN (2) CN102702119B (fr)
AR (1) AR057882A1 (fr)
AU (1) AU2006311481B2 (fr)
BR (2) BR122013025375B8 (fr)
CA (1) CA2590511C (fr)
CY (4) CY1115004T1 (fr)
DK (2) DK2340828T3 (fr)
EC (1) ECSP14019136A (fr)
ES (2) ES2823749T3 (fr)
FR (2) FR16C0018I2 (fr)
GT (1) GT200700055A (fr)
HR (2) HRP20140274T1 (fr)
HU (3) HUE050870T2 (fr)
IL (2) IL184027A (fr)
JO (1) JO3492B1 (fr)
LT (3) LT2340828T (fr)
LU (1) LUC00195I2 (fr)
MA (1) MA30128B1 (fr)
MX (1) MX2007008075A (fr)
MY (1) MY145462A (fr)
NO (3) NO337288B1 (fr)
NZ (2) NZ594006A (fr)
PE (2) PE20190374A1 (fr)
PH (1) PH12012501539B1 (fr)
PL (2) PL1948158T3 (fr)
PT (2) PT2340828T (fr)
RU (1) RU2503668C2 (fr)
SG (1) SG10201402055YA (fr)
SI (2) SI1948158T1 (fr)
TN (1) TNSN07264A1 (fr)
TW (2) TWI418348B (fr)
WO (1) WO2007056546A1 (fr)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (fr) * 2006-03-10 2007-09-20 Novartis Ag Combinaison de composes organiques
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
JP2010538071A (ja) 2007-09-07 2010-12-09 セラヴァンス， インコーポレーテッド 二重作用性降圧剤
FI3067043T3 (fi) * 2007-11-06 2023-03-18 Novartis Ag Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia
CA2705921A1 (fr) * 2007-12-11 2009-06-18 Theravance, Inc. Derives de benzimidazole a double effet et leur utilisation en tant qu'antihypertenseurs
AR070176A1 (es) 2008-01-17 2010-03-17 Novartis Ag Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis
JP2011518884A (ja) 2008-04-29 2011-06-30 セラヴァンス， インコーポレーテッド 二重活性抗高血圧剤
WO2010011821A2 (fr) * 2008-07-24 2010-01-28 Theravance, Inc. Agents anti-hypertensifs à double action
UY32660A (es) 2009-05-28 2010-12-31 Novartis Ag Derivados aminobutricos sustituidos como inhibidores de neprilisina
ME01923B (me) * 2009-05-28 2015-05-20 Novartis Ag Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
JP5833000B2 (ja) 2009-07-07 2015-12-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 二重に作用するピラゾール抗高血圧症薬
WO2011011232A1 (fr) 2009-07-22 2011-01-27 Theravance, Inc. Agents antihypertenseurs à double action à base d'oxazole
EP2281558A1 (fr) * 2009-08-06 2011-02-09 Laboratorios Del. Dr. Esteve, S.A. Composés pharmaceutique de O-desméthyl-tramadol et inhibiteurs COX
JO2967B1 (en) * 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2526095A1 (fr) 2010-01-19 2012-11-28 Theravance, Inc. Agents antihypertenseurs de thiophène, pyrrole, thiazole et furane à double action
RU2564941C2 (ru) * 2010-08-24 2015-10-10 Новартис Аг Лечение гипертензии и/или предотвращение и лечение сердечной недостаточности у млекопитающего, получающего терапию антикоагулянтами
MX2013005165A (es) 2010-11-10 2013-07-05 Theravance Inc Formas cristalinas de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico.
US8877815B2 (en) * 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) * 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CA2817368C (fr) 2010-12-15 2019-12-31 Theravance, Inc. Inhibiteurs de neprilysine
CA2819153A1 (fr) 2010-12-15 2012-06-21 Theravance, Inc. Inhibiteurs de neprilysine
WO2012154249A1 (fr) 2011-02-17 2012-11-15 Theravance, Inc. Dérivés aminobutyriques substitués utilisés en tant qu'inhibiteurs de néprilysine
WO2012112742A1 (fr) 2011-02-17 2012-08-23 Theravance, Inc. Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
PH12013502325A1 (en) 2011-05-13 2014-02-10 Eb Ip Hybritabs B V Drug delivery system
WO2012166390A1 (fr) 2011-05-31 2012-12-06 Theravance, Inc. Inhibiteurs de néprilysine
ES2642883T3 (es) 2011-05-31 2017-11-20 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
ES2653215T3 (es) 2011-05-31 2018-02-06 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
AR089954A1 (es) 2012-02-15 2014-10-01 Theravance Inc Forma cristalina del ester 5-metil-2-oxo-[1,3]dioxol-4-ilmetilico del acido (2s,4r)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1h-[1,2,3]triazol-4-carbonil)amino]pentanoico
WO2013148768A1 (fr) 2012-03-28 2013-10-03 Theravance, Inc. Formes cristallines de l'ester isopropylique de l'acide (r)-3-[n-(3'-chlorobiphényl-4-ylméthyl)-n'-(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxypropionique
EP2649996A1 (fr) * 2012-04-11 2013-10-16 Laboratorios Del. Dr. Esteve, S.A. Formes cristallines de sartans de type Telmisartan avec des bêta-bloquants
ES2609810T3 (es) 2012-05-31 2017-04-24 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina donadores de óxido nítrico
US8871792B2 (en) 2012-06-08 2014-10-28 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
PL2864292T3 (pl) 2012-06-08 2017-10-31 Theravance Biopharma R&D Ip Llc Inhibitory neprylizyny
AR092073A1 (es) 2012-08-08 2015-03-18 Theravance Inc Inhibidores de neprilisina
DK2887961T3 (da) 2012-08-24 2021-07-19 Novartis Ag Nep-inhibitorer til behandling af sygdomme, der er kendetegnet ved atrieforstørrelse eller -remodellering
CA2900226A1 (fr) 2013-02-14 2014-08-21 Novartis Ag Derives de l'acide butanoique bisphenyle substitue utiles en tant qu'inhibiteurs de nep presentant une meilleure efficacite in vivo
LT2956464T (lt) 2013-02-14 2018-07-10 Novartis Ag Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai
RS56300B1 (sr) 2013-03-05 2017-12-29 Theravance Biopharma R&D Ip Llc Inhibitori neprilizina
RS65037B1 (sr) 2013-08-26 2024-02-29 Novartis Ag Lečenje kardiovaskularnih oboljenja
US20160206597A1 (en) * 2013-08-26 2016-07-21 Toni Lynne Bransford New Use
SG11201605965UA (en) 2014-01-30 2016-08-30 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
MX2016009759A (es) 2014-01-30 2016-11-17 Theravance Biopharma R&D Ip Llc Inhibidores de neprilisina.
CN106414416B (zh) * 2014-09-09 2020-03-27 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
WO2016074651A1 (fr) 2014-11-14 2016-05-19 Zentiva, K.S. Procédé de préparation, d'isolation et de purification de formes pharmaceutiquement applicables de ahu-377
CN110922366B (zh) 2014-12-08 2023-02-03 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
WO2016051393A2 (fr) * 2014-12-26 2016-04-07 Crystal Pharmatech Inc. Forme cristalline iv de complexe supramoléculaire de trisodium comprenant du valsartan et ahu-377 ainsi que procédés associés
CN104473938B (zh) * 2014-12-30 2017-06-09 北京瑞都医药科技有限公司 一种治疗慢性心衰药物及其制备方法
WO2016116942A1 (fr) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Nouveaux composés pharmaceutiques comprenant du ticagrélor avec des sels d'aspirine
CN105982891A (zh) * 2015-01-30 2016-10-05 王召印 阿利沙坦脂和脑啡肽酶抑制剂或其前药的药物组合物
US10562866B2 (en) * 2015-02-06 2020-02-18 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
MX372773B (es) 2015-02-11 2020-06-29 Theravance Biopharma R&D Ip Llc Ácido (2s, 4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico.
CN105985225A (zh) * 2015-02-12 2016-10-05 博瑞生物医药（苏州）股份有限公司 一种lcz-696及其中间体的制备方法
CN105884644B (zh) * 2015-02-15 2020-06-09 深圳信立泰药业股份有限公司 一种中性内肽酶抑制剂盐优势形态及其制备方法
MX370065B (es) 2015-02-19 2019-11-29 Theravance Biopharma R&D Ip Llc Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico.
CN106032361A (zh) * 2015-03-11 2016-10-19 齐鲁制药有限公司 Lcz-696的新晶型及其制备方法
CN110801452B (zh) * 2015-03-12 2023-01-13 深圳信立泰药业股份有限公司 一种含有阿利沙坦酯水解产物或其水解产物盐的药物组合物及其用途
JP2018509466A (ja) * 2015-03-20 2018-04-05 クリスタル ファーマテック カンパニー、リミテッドＣｒｙｓｔａｌ Ｐｈａｒｍａｔｅｃｈ Ｃｏ．， Ｌｔｄ． Ａｈｕ３７７の結晶形、その製造方法及び用途
WO2016151525A1 (fr) * 2015-03-26 2016-09-29 Dr. Reddy’S Laboratories Limited Forme cristalline de lcz-696
PT3294283T (pt) 2015-05-11 2023-06-07 Novartis Ag Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca
EP3302460A1 (fr) 2015-05-29 2018-04-11 Novartis AG Sacubitril et valsartan pour le traitement d'une maladie métabolique
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
KR102254062B1 (ko) * 2015-06-12 2021-05-20 테바 파마슈티컬스 인터내셔널 게엠베하 삼나트륨 발사르탄:사쿠비트릴의 고체 형태
WO2016203500A2 (fr) 2015-06-19 2016-12-22 Actavis Group Ptc Ehf. Préparation de sacubitril ou de son sel et nouveaux intermédiaires dans la préparation de sacubitril
HUE052222T2 (hu) * 2015-07-02 2021-04-28 Novartis Ag Sacubitril kalciumsók
CN106316973A (zh) * 2015-07-07 2017-01-11 江苏柯菲平医药股份有限公司 血管紧张素受体拮抗剂和nep抑制剂药物晶型及其制备
WO2017006254A1 (fr) 2015-07-08 2017-01-12 Novartis Ag Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
CN106074421A (zh) * 2015-07-11 2016-11-09 凌莉 一种提高稳定性的药物组合物
CN106176725A (zh) * 2015-07-11 2016-12-07 凌莉 一种提高稳定性的药物组合物及其制备方法和用途
CN106176654A (zh) * 2015-07-11 2016-12-07 凌莉 含有化合物a的固体药物组合物及其制备方法
CN106176723A (zh) * 2015-07-11 2016-12-07 凌莉 一种固体药物组合物及其制备方法
WO2017009784A1 (fr) 2015-07-14 2017-01-19 Cadila Healthcare Limited Formes à l'état solide de sel de trisodium du complexe valsartan/sacubitril et de sacubitril
EP3117823A1 (fr) 2015-07-17 2017-01-18 Quimica Sintetica, S.A. Dispersion solide amorphe comprenant un bloqueur du récepteur de l'angiotensine et d'un inhibiteur d'endopeptidase neutre
WO2017012600A1 (fr) 2015-07-20 2017-01-26 Zentiva, K.S. Composition pharmaceutique contenant du valsartan et du sacubitril et procédés de préparation et de stabilisation correspondants
HRP20201932T4 (hr) 2015-07-23 2024-02-16 Bayer Pharma Aktiengesellschaft Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba
CN106397248A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种lcz696结晶粉末及其制备方法
CN105168205A (zh) * 2015-08-18 2015-12-23 泰力特医药（湖北）有限公司 一种血管紧张素ii受体和脑啡肽酶受体双重抑制剂lcz696的制备方法
WO2017033212A1 (fr) * 2015-08-26 2017-03-02 Actavis Group Ptc Ehf. Préparation de sacubitril et de son sel et nouveau composés utilisés dans le procédé
WO2017037596A1 (fr) * 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Dispersion solide amorphe de lcz-696
KR102569599B1 (ko) * 2015-08-28 2023-08-21 헤테로 랩스 엘티디. 이중-작용 안지오텐신 수용체-네프릴리신 저해제 화합물의 제조를 위한 공정
US10596151B2 (en) 2015-08-28 2020-03-24 Novartis Ag Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
WO2017042700A1 (fr) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Formes solides de valsartan et de sacubitril
WO2017051326A1 (fr) 2015-09-23 2017-03-30 Novartis Ag Nouveaux procédés et intermédiaires utiles dans la synthèse d'inhibiteurs d'endopeptidase neutre (nep)
CN106580908A (zh) * 2015-10-16 2017-04-26 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (fr) 2015-11-20 2017-05-26 Lupin Limited Complexe de sacubitril-valsartan amorphe et son procédé de préparation
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CN106854187B (zh) * 2015-12-08 2020-04-14 苏州晶云药物科技股份有限公司 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法
CN105348209B (zh) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
MX2018007129A (es) 2015-12-11 2018-11-09 Zentiva Ks Formas solidas de ester etilico del acido (2r,4s)-5-(bifenil-4-il) -4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un metodo de preparacion.
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
CN105622535B (zh) * 2015-12-28 2018-08-03 重庆两江药物研发中心有限公司 一种lcz696的制备方法
CN114315801B (zh) * 2016-01-20 2023-06-20 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法
CN105646384A (zh) * 2016-01-27 2016-06-08 北京沃邦医药科技有限公司 一种脑啡肽酶抑制剂与血管紧张素ⅱ受体拮抗剂共晶化合物的精制方法
ES3036922T3 (en) * 2016-02-03 2025-09-25 Novartis Ag New use of a combination of sacubitril and valsartan
CN107033094A (zh) * 2016-02-04 2017-08-11 南京卡文迪许生物工程技术有限公司 一种药物共晶的晶型及其制备方法和组合物
WO2017141193A1 (fr) * 2016-02-16 2017-08-24 Sun Pharmaceutical Industries Limited Procédé de préparation de sacubitril ou de ses sels
WO2017154017A1 (fr) * 2016-03-07 2017-09-14 Msn Laboratories Limited Procédé de préparation du (4-{[(1s,3r)-1-([1,1'-biphényl]-4-ylméthyl)-4-éthoxy-3-méthyl-4-oxobutyl]amino}-4-oxobutanoate)-(n-pentanoyl-n-{[2'-(1h-tétrazol-1-id-5-yl)[1,1'-biphényl]-4-yl]méthyl}-l-valinate) trisodique et ses polymorphes
MX377177B (es) 2016-03-08 2025-03-07 Theravance Biopharma R&D Ip Llc Acido (2s,4r)-5-(5'-cloro-2'-fluoro-[1,1'-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxiisoxazol-5-carboxamido)-2-metilpentanoico cristalino, y sus usos.
WO2017191619A2 (fr) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited Procédé de préparation d'un sel de sacubitril et de valsartan
WO2017191620A1 (fr) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited Forme cristalline d'un sel de sacubitril et procédé pour le préparer
EP3248592A1 (fr) 2016-05-25 2017-11-29 EB IP Hybritabs B.V. Procédé pour la préparation de systèmes d'administration de médicament comprenant un composé de testostérone présent dans une couche ou une partie externe, ainsi que de tels systèmes d'administration de médicaments
US20190256454A1 (en) 2016-07-05 2019-08-22 Novartis Ag New process for early sacubitril intermediates
CN106177960B (zh) * 2016-08-01 2019-01-08 珠海赛隆药业股份有限公司（长沙）医药研发中心 血管紧张素受体拮抗剂和脑啡肽酶抑制剂的复合物及其用途
JP6945619B2 (ja) 2016-08-17 2021-10-06 ノバルティス アーゲー Ｎｅｐ阻害剤合成のための新規な方法および中間体
EP3508479A4 (fr) * 2016-09-02 2020-02-19 Noratech Pharmaceuticals, Inc. Formes cristallines de sel disodique de valsartan
EP3522886A4 (fr) 2016-10-10 2020-02-19 Laurus Labs Limited Forme amorphe stable d'un complexe de sacubitril-valsartan trisodique et ses procédés de préparation
WO2018069937A1 (fr) 2016-10-13 2018-04-19 Mylan Laboratories Limited Dispersions solides de sacubitril/valsartan trisodique et procédé de leur préparation
EP3532454A4 (fr) 2016-10-28 2020-11-25 Biocon Limited Sacubitril/valsartan trisodique amorphe et son procédé de préparation
CN106518709A (zh) * 2016-11-07 2017-03-22 济南益新医药技术有限公司 一种无定形沙库比曲缬沙坦钠盐复合物的制备方法
JP7138106B2 (ja) 2016-12-23 2022-09-15 ノバルティス アーゲー 初期サクビトリル中間体のための新規な方法
WO2018119178A1 (fr) * 2016-12-23 2018-06-28 StemBios Technologies, Inc. Utilisation de cellules souches somatiques pour diminuer le taux de néprilysine
CN106674206B (zh) * 2016-12-30 2021-01-19 顾国明 一种治疗心衰的共晶体药物
CN111592500A (zh) * 2017-01-03 2020-08-28 上海博志研新药物技术有限公司 ARB-NEPi复合物、晶型、制备方法及应用
CN106800537B (zh) * 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
WO2018153895A1 (fr) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec un inhibiteur de l'endopeptidase neutre et/ou un antagoniste du récepteur de l'angiotensine ii
WO2018178295A1 (fr) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Extrudat thermofusible stable contenant du valsartan et du sacubitril
WO2018211479A1 (fr) * 2017-05-19 2018-11-22 Lupin Limited Compositions stabilisées d'inhibiteurs de l'angiotensine ii et d'inhibiteurs de l'endopeptidase neutre, et leur procédé de préparation
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
MX391562B (es) * 2017-07-28 2025-03-21 Synthon Bv Composicion farmaceutica que comprende sacubitril y valsartan
US10510575B2 (en) 2017-09-20 2019-12-17 Applied Materials, Inc. Substrate support with multiple embedded electrodes
EP3694493A1 (fr) 2017-10-13 2020-08-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Comprimé contenant du valsartan et du sacubitril
CN107935958B (zh) * 2017-11-30 2021-02-09 中国药科大学 一种缬沙坦葛根素钠盐复合物及其制备方法
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US10555412B2 (en) 2018-05-10 2020-02-04 Applied Materials, Inc. Method of controlling ion energy distribution using a pulse generator with a current-return output stage
WO2019239432A1 (fr) 2018-06-14 2019-12-19 Cipla Limited Complexe de valsartan et de sacubitril trisodique et composition pharmaceutique extrudée à chaud comprenant celui-ci
GB201810326D0 (en) 2018-06-22 2018-08-08 Johnson Matthey Plc Crystalline form of sacubitril, its preparation and use
WO2020039386A1 (fr) 2018-08-23 2020-02-27 Novartis Ag Nouvelle utilisation pharmaceutique pour le traitement d'une insuffisance cardiaque
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
CN109265406B (zh) * 2018-09-03 2020-09-22 石药集团中奇制药技术（石家庄）有限公司 一种沙库巴曲缬沙坦钠新晶型及其制备方法和用途
US11476145B2 (en) 2018-11-20 2022-10-18 Applied Materials, Inc. Automatic ESC bias compensation when using pulsed DC bias
KR20200073676A (ko) 2018-12-14 2020-06-24 엠에프씨 주식회사 발사탄 및 사쿠비트릴을 포함하는 고체 분산체 및 이를 포함하는 약학 조성물 및 이의 제조 방법
JP7451540B2 (ja) 2019-01-22 2024-03-18 アプライド マテリアルズ インコーポレイテッド パルス状電圧波形を制御するためのフィードバックループ
US11508554B2 (en) 2019-01-24 2022-11-22 Applied Materials, Inc. High voltage filter assembly
CN109912525A (zh) * 2019-03-13 2019-06-21 陈文辉 一种lcz696新晶型及其制备方法
KR102543230B1 (ko) 2019-05-24 2023-06-14 주식회사 파마코스텍 발사르탄/사쿠비트릴 3소듐염 수화물의 결정형 및 그 제조방법
WO2020238885A1 (fr) * 2019-05-30 2020-12-03 深圳信立泰药业股份有限公司 Procédé de traitement de complexe d'un métabolite antagoniste du récepteur de l'angiotensine ii et d'un inhibiteur de nep
WO2020238884A1 (fr) * 2019-05-30 2020-12-03 深圳信立泰药业股份有限公司 Nouvelle utilisation d'un complexe d'un métabolite antagoniste du récepteur de l'angiotensine ii et d'un inhibiteur de nep
EP3766484B1 (fr) 2019-07-19 2021-08-25 Zentiva, K.S. Forme posologique pharmaceutique solide comprenant du valsartan et du sacubitril
AU2020348813B2 (en) 2019-09-20 2025-09-11 Shenzhen Salubris Pharmaceuticals Co. Ltd Uses of complex of angiotensin II receptor antagonist metabolite and NEP inhibitor in treating heart failure
WO2021126884A1 (fr) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan pour traiter l'hypertension pulmonaire accompagnée d'une insuffisance cardiaque au moyen d'une fraction d'éjection préservée (ph-hf-pef)
WO2021143898A1 (fr) * 2020-01-19 2021-07-22 深圳信立泰药业股份有限公司 Nouvelle forme cristalline de complexe de métabolite d'arb et d'inhibiteur de nep et son procédé de préparation
KR102149126B1 (ko) 2020-02-05 2020-08-28 유니셀랩 주식회사 새로운 사쿠비트릴 칼슘/발사르탄 공결정
KR20210101164A (ko) 2020-02-07 2021-08-18 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20200020746A (ko) 2020-02-07 2020-02-26 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
CN111253330B (zh) * 2020-02-29 2023-01-24 广州白云山天心制药股份有限公司 沙坦类药物的新晶型及其制备方法和用途
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR102155474B1 (ko) 2020-04-28 2020-09-11 유니셀랩 주식회사 사쿠비트릴/발사르탄 공동무정형
JP7064527B2 (ja) * 2020-05-01 2022-05-10 ノバルティス アーゲー サクビトリルカルシウム塩
WO2021254409A1 (fr) * 2020-06-18 2021-12-23 深圳信立泰药业股份有限公司 Composition pharmaceutique de complexe et son procédé de préparation
KR20220012821A (ko) 2020-07-23 2022-02-04 주식회사 종근당 이중 작용 복합 화합물의 결정형 및 이의 제조방법
KR102215623B1 (ko) * 2020-07-24 2021-02-15 유니셀랩 주식회사 사쿠비트릴 칼슘염 및 사쿠비트릴 유리염기와 발사르탄을 공동분자로 사용한 새로운 신규 공결정 형태
US11462388B2 (en) 2020-07-31 2022-10-04 Applied Materials, Inc. Plasma processing assembly using pulsed-voltage and radio-frequency power
TWI894333B (zh) * 2020-08-17 2025-08-21 大陸商深圳信立泰藥業股份有限公司 血管收縮素ii受體拮抗劑代謝產物與ｎｅｐ抑制劑的複合物用於心臟衰竭的應用
KR102858594B1 (ko) 2020-10-08 2025-09-11 한미약품 주식회사 사쿠비트릴 및 발사르탄 나트륨염을 포함하는 경구용 고형제제
US11798790B2 (en) 2020-11-16 2023-10-24 Applied Materials, Inc. Apparatus and methods for controlling ion energy distribution
US11901157B2 (en) 2020-11-16 2024-02-13 Applied Materials, Inc. Apparatus and methods for controlling ion energy distribution
CN115461052B (zh) * 2020-11-25 2023-12-22 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko) 2021-01-20 2023-01-10 주식회사 대웅제약 Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법
US11495470B1 (en) 2021-04-16 2022-11-08 Applied Materials, Inc. Method of enhancing etching selectivity using a pulsed plasma
WO2022224274A1 (fr) 2021-04-20 2022-10-27 Mylan Laboratories Limited Formes polymorphes de sacubitril-telmisartan (1 : 1)
US11948780B2 (en) 2021-05-12 2024-04-02 Applied Materials, Inc. Automatic electrostatic chuck bias compensation during plasma processing
US11791138B2 (en) 2021-05-12 2023-10-17 Applied Materials, Inc. Automatic electrostatic chuck bias compensation during plasma processing
US11967483B2 (en) 2021-06-02 2024-04-23 Applied Materials, Inc. Plasma excitation with ion energy control
US12148595B2 (en) 2021-06-09 2024-11-19 Applied Materials, Inc. Plasma uniformity control in pulsed DC plasma chamber
US20220399186A1 (en) 2021-06-09 2022-12-15 Applied Materials, Inc. Method and apparatus to reduce feature charging in plasma processing chamber
US11984306B2 (en) 2021-06-09 2024-05-14 Applied Materials, Inc. Plasma chamber and chamber component cleaning methods
US11810760B2 (en) 2021-06-16 2023-11-07 Applied Materials, Inc. Apparatus and method of ion current compensation
US11569066B2 (en) 2021-06-23 2023-01-31 Applied Materials, Inc. Pulsed voltage source for plasma processing applications
US11776788B2 (en) 2021-06-28 2023-10-03 Applied Materials, Inc. Pulsed voltage boost for substrate processing
KR102756994B1 (ko) 2021-07-22 2025-01-22 대봉엘에스 주식회사 사쿠비트릴, 발사르탄, 및 니코틴아미드의 공동무정형
KR102399717B1 (ko) 2021-08-10 2022-05-19 대봉엘에스 주식회사 사쿠비트릴 및 아질사르탄 복합 약제학적 조성물, 및 이의 제조방법
US11476090B1 (en) 2021-08-24 2022-10-18 Applied Materials, Inc. Voltage pulse time-domain multiplexing
WO2023025220A1 (fr) * 2021-08-26 2023-03-02 深圳信立泰药业股份有限公司 Composition pharmaceutique d'ibuprofène et d'antagoniste d'ions calcium, et application
US12106938B2 (en) 2021-09-14 2024-10-01 Applied Materials, Inc. Distortion current mitigation in a radio frequency plasma processing chamber
US11694876B2 (en) 2021-12-08 2023-07-04 Applied Materials, Inc. Apparatus and method for delivering a plurality of waveform signals during plasma processing
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
US11972924B2 (en) 2022-06-08 2024-04-30 Applied Materials, Inc. Pulsed voltage source for plasma processing applications
US12315732B2 (en) 2022-06-10 2025-05-27 Applied Materials, Inc. Method and apparatus for etching a semiconductor substrate in a plasma etch chamber
US12272524B2 (en) 2022-09-19 2025-04-08 Applied Materials, Inc. Wideband variable impedance load for high volume manufacturing qualification and on-site diagnostics
US12111341B2 (en) 2022-10-05 2024-10-08 Applied Materials, Inc. In-situ electric field detection method and apparatus
WO2024210557A1 (fr) 2023-04-05 2024-10-10 한미약품 주식회사 Formulation combinée comprenant du sacubitril-valsartan et un inhibiteur de sglt-2 ayant une stabilité et un taux de dissolution améliorés
KR20250066976A (ko) * 2023-11-07 2025-05-14 주식회사 노브메타파마 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 당뇨병성 신증의 예방, 개선 또는 치료용 조성물
EP4652990A1 (fr) 2024-05-24 2025-11-26 Genepharm S.A. Emballage de composition solide de valsartan et de sacubitril

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2499058A (en) 1950-02-28 B-haloxantfflne salts of diarylalkyl
US1954909A (en) 1929-11-14 1934-04-17 Adler Oscar Processes for the producing of molecular compounds of the salts of phenyl-quinolinecarboxylic acids with alkylated pyrazolones and alkylated amino-pyrazolones
NL76613C (fr) 1948-07-01
US2534813A (en) 1950-01-21 1950-12-19 Searle & Co 8-haloxanthine salts of cyclic-aminoalkyl benzohydryl ethers and the production thereof
US3057731A (en) 1958-03-27 1962-10-09 Skanska Attikfabriken Ab Preparation of bakery products
WO1981000562A1 (fr) 1979-08-20 1981-03-05 Abbott Lab Sel melange d'acide valproique
US4610816A (en) 1980-12-18 1986-09-09 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
DE3116334A1 (de) * 1981-04-24 1982-11-18 Gefra B.V.,, s'Gravenzande "vorrichtung zum befestigen einer seitenfuehrung, einer foerdereinrichtung an einer stuetze"
ZA84670B (en) 1983-01-31 1985-09-25 Merck & Co Inc Thiorphan analogs as enkephalinase and angiotensin converting enzyme inhibitors
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4929641B1 (en) 1988-05-11 1994-08-30 Schering Corp Mercapto-acylamino acid antihypertensives
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4740499A (en) 1986-07-28 1988-04-26 Monsanto Company Method of enhancing the bioactivity of atrial peptides
GB8811873D0 (en) 1988-05-19 1988-06-22 Pfizer Ltd Therapeutic agents
GB2218983A (en) 1988-05-27 1989-11-29 Pfizer Ltd Spiro-substituted glutaramides as diuretics
GB8812597D0 (en) 1988-05-27 1988-06-29 Pfizer Ltd Therapeutic agents
EP0361365A1 (fr) 1988-09-30 1990-04-04 E.R. SQUIBB & SONS, INC. Composés d'acides aminobenzoiques et aminocyclohexane carboxyliques, compositions, et méthode d'application
GB8903740D0 (en) 1989-02-18 1989-04-05 Pfizer Ltd Therapeutic agents
PH30484A (en) 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
FR2658571B1 (fr) 1990-02-21 1992-04-24 Bendix Europ Services Tech
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
HUT59656A (en) 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing s/+/-phenyl-alkanoic acids and alpha-amino-acids containing complexes and pharmaceutical compositions containing them as active components
WO1992013564A1 (fr) 1991-02-06 1992-08-20 Schering Corporation Combinaison d'un antagoniste d'angiotensine ii ou d'un inhibiteur de renine avec un inhibiteur d'endopeptidase neutre
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
EP0509442A1 (fr) 1991-04-16 1992-10-21 Schering Corporation Utilisation d'inhibiteurs de l'endopeptidase neutre dans le traitement de la nephrotoxicité
US5294632A (en) 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
US5225401A (en) 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
US5273990A (en) 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
US5250522A (en) 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
GB9123353D0 (en) 1991-11-04 1991-12-18 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
WO1993010773A1 (fr) 1991-12-06 1993-06-10 Schering-Plough S.P.A. Utilisation d'inhibiteurs d'endopeptidases neutres dans le traitement de l'hipertrophie ventriculaire gauche
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5376293A (en) 1992-09-14 1994-12-27 State Of South Dakota As Represented By The Department Of Transportation Deicer
DE4233296C1 (de) 1992-10-02 1994-03-31 Heitland Und Petre Int Gmbh Behälter für Kosmetikprodukte
WO1994015908A1 (fr) 1993-01-14 1994-07-21 Yoshitomi Pharmaceutical Industries, Ltd. Derive de propionamide et son utilisation medicinale
JPH06234754A (ja) 1993-02-10 1994-08-23 Dai Ichi Seiyaku Co Ltd 複素環式カルボン酸誘導体
CN1046119C (zh) 1993-07-22 1999-11-03 中国科学院广州电子技术研究所 聚磷酸盐复盐及其制造方法
IT1266571B1 (it) 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
JP2810302B2 (ja) 1993-10-01 1998-10-15 ティーディーケイ株式会社 小型ポンプ
JP3576193B2 (ja) 1993-12-03 2004-10-13 第一製薬株式会社 ビフェニルメチル置換バレリルアミド誘導体
CA2168066A1 (fr) * 1995-02-08 1996-08-09 James R. Powell Traitement de l'hypertension et de l'insuffisance cardiaque globale
US6558699B2 (en) 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
DE69926750T2 (de) 1998-06-17 2006-06-29 Bristol-Myers Squibb Co. Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten
PT2322174E (pt) 1998-07-10 2015-10-27 Novartis Pharma Gmbh Utilização combinada de valsartan e bloqueadores do canal de cálcio com objetivos terapêuticos
CN1069647C (zh) 1998-08-31 2001-08-15 靳广毅 一种具有广谱抗菌作用的化合物及其用途
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
CN1352640A (zh) 1999-05-27 2002-06-05 辉瑞产品公司 氨氯地平和阿托伐他汀的共同前体药物
EP1267855A2 (fr) * 2000-04-03 2003-01-02 Bristol-Myers Squibb Company Inhibiteurs de vasopeptidase pour traiter l'hypertension systolique isolee
DK1313714T3 (da) * 2000-07-19 2008-12-15 Novartis Ag Valsartansalte
DE10050246C1 (de) 2000-10-11 2002-06-20 Nutrinova Gmbh Calciumdoppelsalze, Verfahren zu ihrer Herstellung und ihre Verwendung zur Konservierung
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6774112B2 (en) 2001-04-11 2004-08-10 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
BR0213357A (pt) 2001-10-18 2004-10-26 Novartis Ag Compostos orgânicos
WO2003059345A1 (fr) * 2002-01-17 2003-07-24 Novartis Ag Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
WO2004078161A1 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions co-cristallines pharmaceutiques de medicaments, notamment de carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophene, aspirine, flurbiprofene, phenytoine et ibuprofene
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
EP1494998A2 (fr) 2002-03-01 2005-01-12 University Of South Florida Phases solides multicomposants contentant au moins un principe pharmaceutiquement actif
WO2003089417A1 (fr) 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Nouvelles formes cristallines de (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
TWI299663B (en) 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP2316488A1 (fr) 2002-05-17 2011-05-04 Novartis AG Composition pharmaceutique comprenant un inhibiteur de rénine, un agent de blocage du canal du calcium et un diurétique
CN1159313C (zh) 2002-08-27 2004-07-28 何广卫 地洛他定多元酸碱金属或碱土金属盐复合盐及其药用组合物
GB0230025D0 (en) 2002-12-23 2003-01-29 Pfizer Ltd Novel pharmaceuticals
EP1631260A2 (fr) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
US20040242661A1 (en) 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
US20050165075A1 (en) 2003-03-31 2005-07-28 Hetero Drugs Limited Novel amorphous form of valsartan
CN1247596C (zh) 2003-05-15 2006-03-29 中国药品生物制品检定所 一种具有螯合结晶水合物的头孢菌素及其制备方法
EP1631556A1 (fr) * 2003-05-16 2006-03-08 Novartis AG Composition pharmaceutique comportant du valsartan
WO2005049587A1 (fr) 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Procede de preparation de tetrazole de biphenyle
CN1246482C (zh) 2004-05-08 2006-03-22 山东大学齐鲁医院 单个核细胞白细胞相容性抗原a和b特异核糖核酸检测方法
CN1279045C (zh) 2004-07-30 2006-10-11 广州白云山制药股份有限公司 头孢硫脒复盐及其制造方法
CN100500669C (zh) 2004-12-10 2009-06-17 山东大学 一种丹酚酸黄连素复盐及其制备方法与应用
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
JP2006234754A (ja) 2005-02-28 2006-09-07 Tokyo Keiso Co Ltd 超音波流量計
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN100391961C (zh) 2005-11-16 2008-06-04 天津大学 五水头孢唑林钠晶体结构及晶体分子组装制备方法
JP2007157459A (ja) 2005-12-02 2007-06-21 Sony Corp 非水電解質電池
CN106414416B (zh) 2014-09-09 2020-03-27 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
CN110922366B (zh) 2014-12-08 2023-02-03 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
US10562866B2 (en) 2015-02-06 2020-02-18 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
JP2018509466A (ja) 2015-03-20 2018-04-05 クリスタル ファーマテック カンパニー、リミテッドＣｒｙｓｔａｌ Ｐｈａｒｍａｔｅｃｈ Ｃｏ．， Ｌｔｄ． Ａｈｕ３７７の結晶形、その製造方法及び用途
KR102254062B1 (ko) 2015-06-12 2021-05-20 테바 파마슈티컬스 인터내셔널 게엠베하 삼나트륨 발사르탄:사쿠비트릴의 고체 형태
WO2017009784A1 (fr) 2015-07-14 2017-01-19 Cadila Healthcare Limited Formes à l'état solide de sel de trisodium du complexe valsartan/sacubitril et de sacubitril
CN105037289B (zh) 2015-07-17 2017-08-22 华东理工大学 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型
WO2017042700A1 (fr) 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Formes solides de valsartan et de sacubitril
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
WO2017154017A1 (fr) 2016-03-07 2017-09-14 Msn Laboratories Limited Procédé de préparation du (4-{[(1s,3r)-1-([1,1'-biphényl]-4-ylméthyl)-4-éthoxy-3-méthyl-4-oxobutyl]amino}-4-oxobutanoate)-(n-pentanoyl-n-{[2'-(1h-tétrazol-1-id-5-yl)[1,1'-biphényl]-4-yl]méthyl}-l-valinate) trisodique et ses polymorphes
EP3522886A4 (fr) 2016-10-10 2020-02-19 Laurus Labs Limited Forme amorphe stable d'un complexe de sacubitril-valsartan trisodique et ses procédés de préparation
CN111592500A (zh) 2017-01-03 2020-08-28 上海博志研新药物技术有限公司 ARB-NEPi复合物、晶型、制备方法及应用
CN109912525A (zh) 2019-03-13 2019-06-21 陈文辉 一种lcz696新晶型及其制备方法

Also Published As

Publication number Publication date
CN102702119A (zh) 2012-10-03
JP2011252013A (ja) 2011-12-15
NO20151656A1 (no) 2007-09-10
CY2021003I1 (el) 2021-05-05
TW200803834A (en) 2008-01-16
US20200016110A1 (en) 2020-01-16
KR20080075055A (ko) 2008-08-14
US20180344679A1 (en) 2018-12-06
LTPA2021502I1 (lt) 2021-02-10
US20220331282A1 (en) 2022-10-20
KR20130116381A (ko) 2013-10-23
CN102702119B (zh) 2016-01-20
TNSN07264A1 (en) 2008-12-31
EP1948158B1 (fr) 2014-01-29
US20220257551A1 (en) 2022-08-18
US9388134B2 (en) 2016-07-12
PL2340828T3 (pl) 2021-02-22
BRPI0605921B1 (pt) 2020-08-18
EP1948158A1 (fr) 2008-07-30
LUC00195I2 (fr) 2024-10-04
CY2016014I1 (el) 2016-08-31
US20190374497A1 (en) 2019-12-12
WO2007056546A1 (fr) 2007-05-18
PE20070803A1 (es) 2007-09-10
US20210361610A1 (en) 2021-11-25
RU2012107219A (ru) 2013-09-10
US20190374498A1 (en) 2019-12-12
LT2340828T (lt) 2020-11-10
SG10201402055YA (en) 2014-09-26
ES2449765T3 (es) 2014-03-21
EP2340828B1 (fr) 2020-07-15
CY1123531T1 (el) 2021-05-05
EP3685833A1 (fr) 2020-07-29
TWI554504B (zh) 2016-10-21
CA2590511C (fr) 2013-01-08
NO2016008I2 (no) 2016-05-18
JP2015098485A (ja) 2015-05-28
MX2007008075A (es) 2007-07-13
TW201402111A (zh) 2014-01-16
MA30128B1 (fr) 2009-01-02
NO337288B1 (no) 2016-02-29
US8877938B2 (en) 2014-11-04
ECSP14019136A (es) 2015-12-31
CN101098689A (zh) 2008-01-02
HUS2100003I1 (hu) 2021-03-01
US11096918B2 (en) 2021-08-24
US20250339395A1 (en) 2025-11-06
FR16C0018I1 (fr) 2016-06-24
CN101098689B (zh) 2013-02-13
ES2823749T3 (es) 2021-05-10
KR101432821B1 (ko) 2014-08-26
BRPI0605921A2 (pt) 2009-05-26
HRP20201605T1 (hr) 2020-12-25
PE20190374A1 (es) 2019-03-08
IL184027A (en) 2014-11-30
GT200700055A (es) 2008-09-24
HK1175465A1 (zh) 2013-07-05
US20090156585A1 (en) 2009-06-18
US20160324821A1 (en) 2016-11-10
EP2340828A1 (fr) 2011-07-06
BRPI0605921B8 (pt) 2021-05-25
HRP20140274T1 (hr) 2014-04-25
IL184027A0 (en) 2007-10-31
PH12012501539A1 (en) 2013-06-17
NO2016008I1 (no) 2016-05-18
CY2021003I2 (el) 2023-11-15
PT2340828T (pt) 2020-10-19
JP4824754B2 (ja) 2011-11-30
US20150057322A1 (en) 2015-02-26
HUE050870T2 (hu) 2021-01-28
AU2006311481A1 (en) 2007-05-18
RU2503668C2 (ru) 2014-01-10
NZ594006A (en) 2012-07-27
PL1948158T3 (pl) 2014-06-30
BR122013025375B1 (pt) 2020-12-01
SI1948158T1 (sl) 2014-04-30
US20200016109A1 (en) 2020-01-16
HUS1600025I1 (hu) 2016-06-28
JP2008542447A (ja) 2008-11-27
PT1948158E (pt) 2014-04-04
MY145462A (en) 2012-02-15
FR16C0018I2 (fr) 2017-12-08
LTC2340828I2 (lt) 2024-05-10
NO20073396L (no) 2007-09-10
FR21C1000I2 (fr) 2024-05-24
DK2340828T3 (da) 2020-10-12
TWI418348B (zh) 2013-12-11
HK1121371A1 (en) 2009-04-24
KR101549318B1 (ko) 2015-09-01
BR122013025375B8 (pt) 2021-05-25
LTC1948158I2 (lt) 2022-09-12
AR057882A1 (es) 2007-12-26
CY1115004T1 (el) 2016-08-31
CA2590511A1 (fr) 2007-05-18
AU2006311481B2 (en) 2010-02-25
SI2340828T1 (sl) 2020-11-30
DK1948158T3 (en) 2014-03-10
NZ600626A (en) 2013-11-29
US11642329B2 (en) 2023-05-09
PH12012501539B1 (en) 2019-07-17
NO340315B1 (no) 2017-03-27
IL219782A0 (en) 2012-06-28
JO3492B1 (ar) 2020-07-05

Similar Documents

Publication Publication Date Title
FR21C1000I1 (fr) Combiaisons pharmaceutiques d'un antagoniste du recepteur de l'angiotensine et un inhibiteur de nep
FR24C1038I2 (fr) Antagoniste des récepteurs de l'endothéline et de l'angiotensine ii à base de biphénylsulfonamide pour traiter la glomérulosclérose
MA29034B1 (fr) Posologie d'un agoniste du recepteur s1p
EP2049110A4 (fr) Diazépans pontés antagonistes du récepteur de l'oréxine
PT1857457E (pt) Derivado de benzimidazole e sua utilização como antagonista do receptor a ii
FR15C0048I2 (fr) Anticorps antagonistes de il-17
EP2244575A4 (fr) Antagonistes du récepteur de l'angiotensine ii
BRPI0716815A2 (pt) Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p)
DK2059246T3 (da) Terapeutiske sammensætninger omfattende en specifik endothelin-receptorantagonist og en PDE5-inhibitor
CY2013037I1 (el) Ανταγωνιστης υποδοχεα της αγγειοτενσινης ιι για τη θεραπευτικη αγωγη συστημικων νοσων σε γατες
MA28359A1 (fr) Antagonistes du recepteur a l'hydroisoindoline tachykinine
EP2146572A4 (fr) Antagonistes des récepteurs cgrp hétérocycliques d'anilide bicyclique
EP1809608A4 (fr) Potentialisateurs de pyrimidine et quinoline des recepteurs metabotropiques du glutamate
EP1799672A4 (fr) Antagonistes du recepteur de cgrp
EP2150248A4 (fr) Antagonistes de récepteur de glutamate et procédés d'utilisation
EP1808446A4 (fr) Antagoniste du recepteur il-18 et composition pharmaceutique contenant cet antagoniste
EP2076285A4 (fr) Antagonistes d'anticorps du récepteur 1 de l'interleukine-13
EP1906972A4 (fr) Inhibiteur d'un agoniste du recepteur lpa2 de cftr
EP2331101A4 (fr) Antagonistes du récepteur cgrp d'amide monocyclique
EP2185687A4 (fr) Traitement d'une psychose par un antagoniste de 5ht2a et un agoniste ou un potentialisateur du récepteur métabotrope du glutamate
ZA200704717B (en) Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
EP1828227A4 (fr) Nouveaux antagonistes peptidiques et peptidoïdes du recepteur de la bradykinine b1 et utilisations de ceux-ci
EP1937710A4 (fr) Agonistes peptidiques du récepteur de la kinine b1 et leurs utilisations